Use of Bisphosphonates in Hematology

Fig. 4.1

Soluble vascular endothelial growth factor (sVEGFR1) levels in all groups studied. (From [50], ©2007 Informa Healthcare. Reproduced with permission)
Furthermore to test the hypothesis that in patients with ONJ there may be endothelial-cell interference by BPs, Allegra et al. used flow cytometry to evaluate the number of circulating endothelial cells (CECs). They characterized circulating endothelial progenitor cells (EPCs), which represent more immature cells, expressing the phenotype CD34+133+VEGFR2+. They also identified the more mature CECs, which lose CD133 and start to differentiate into mature endothelial cells. The phenotype of CECs thus is CD34+133-VEGFR2+. EPCs and CECs were found to be higher in MM patients than in either controls or ONJ patients. Moreover, ONJ patients had fewer EPCs than control subjects [51]. Analogous results were obtained by Ziebart et al., who showed that human umbilical vein endothelial cells and EPCs were significantly influenced by BPs at different concentrations compared with the non-treated control cells [52]. Taken together, these data suggest that in patients with ONJ, there is a suppressive effect of BPs on angiogenesis through an action on CECs. This finding is of potential interest because it is well known that in MM angiogenesis governs disease progression and that CECs are increased and vary in parallel with the clinical indicators of disease activity [53, 54].
Finally, an increase in endothelial cell apoptosis was demonstrated in MM patients after BP administration and in patients with ONJ (Fig. 4.2), with a correlation between the number of apoptotic cells and the duration of BP treatment in the latter group [55].

A212517_1_En_4_Fig2_HTML.gif
Fig. 4.2

Evaluation of endothelial progenitor cells (EPC) and annexin V+ circulating endothelial cells (CEC) cells in all groups. a # p < 0.05 vs. controls. Patients with osteonecrosis of the jaw (ONJ) had a higher percentage of EPC/annexin V+ cells (83%). b * p < 0.05 vs. controls and multiple myeloma (MM) patients before bisphosphonates (BPs); ° p < 0.01 vs. controls and MM patients before BPs; $ p < 0.05 vs. MM patients after BPs. (From [55] with permission by S. Karger AG, Basel)
A recent case of bevacizumab-related ONJ highlights the potential of anti-angiogenic action to contribute to oral mucosal breakdown and suggests a cumulative toxicity between BPs and the anti-angiogenic agents commonly used in MM patients, such as thalidomide and lenalidomide [56, 57].
However, ONJ could be caused by a combination of environmental and genetic risk factors [58]. Sarasquete et al. explored the potential role of genetics in the development of ONJ in MM patients under BP therapy. A genome-wide association study was performed analyzing 500,568 single nucleotide polymorphisms (SNPs) in two series of homogeneously treated MM patients, one with and the other without ONJ. Four SNPs that mapped within the cytochrome P450-2C gene (CYP2C8) showed a different distribution between cases and controls, with statistically significant differences. SNP rs1934951 was significantly associated with a higher risk of ONJ development. Genotyping results identified an overrepresentation of the T allele in cases compared with controls (48 vs. 12%). Thus, individuals homozygous for the T allele had an increased likelihood of developing ONJ [59]. CYP2C8 is responsible for the metabolism of several drugs [60], and recent reports have shown that variability in genes encoding CYP2C8 may affect drug pharmacokinetics [61]. Since BPs do not undergo any physicochemical modifications in the body, CYP2C8 polymorphisms would not play a role in their metabolism; however, CYP2C8 gene polymorphisms may affect several biological pathways possibly involved in the development of ONJ in patients treated with BPs [6264].

4.3 The Use of Bisphosphonates in Multiple Myeloma

Current guidelines for BP treatment of MM have been compiled by the National Comprehensive Cancer Network [65], the ASCO [66], the Mayo Clinic [67], the European Society for Medical Oncology [68], and the International Myeloma Working Group [69]. The guidelines for the use of BPs in MM recommend that either PAM or ZOL be given every 3–4 weeks in patients with MM [70]. BPs are not recommended to treat monoclonal gammopathy of undetermined significance (MGUS) or asymptomatic MM. In the absence of visible bone lesions on plain films, if the patient requires chemotherapy, then BP treatment should be initiated [71].
BPs should be given for 2 years and after that at the physician’s discretion, with therapy resumed upon relapse. While the administration of BPs beyond 2 years is not recommended, a subgroup of patients might still benefit from longer treatment. As an alternative to stopping BPs after 2 years, some panel members prefer to continue BP therapy at either a reduced dose or a reduced schedule.
Cafro et al. evaluated the incidence, risk factors, management, and prevention strategies of ONJ in order to optimize the current standard use of BPs in MM. The most important risk factor for ONJ was determined to be the number of BPs infusions [72]. Additional risk factors in cancer patients include the underlying malignancy, chemotherapy, corticosteroids, and systemic or regional infection. Pancytopenia secondary to cancer and/or cancer treatment is a risk for infection and osteomyelitis. Vascular insufficiency due to thrombosis caused by coagulopathies also has been associated with ONJ [73]. Other risk factors are diabetes, smoking, alcohol use, and poor oral hygiene [74]. Nonetheless, the major risk factors for ONJ remain duration of treatment with BPs, the type and dosage of BP used, and dental procedures/trauma [7579]. The risk for ONJ increases with BP treatment duration and has been shown to be 5–15% at 4 years [8087].
A retrospective study of MM patients treated with ZOL on a reduced schedule (infusion every 3 months vs. monthly) showed a decrease in the number of ONJ cases [88]. While ONJ has been reported in patients treated with the oral BP clodronate, such cases are very uncommon [89].
In agreement with the guidelines, a prevention-based strategy was recommended by the panels of experts. Specifically, as the majority of ONJ cases occur after dental surgery [9092], MM patients should receive a comprehensive dental examination before treatment with BPs, in order to identify and treat dental problems that may require surgical or invasive dental procedures. After therapy initiation, unnecessary invasive dental procedures should be avoided.
Montefusco et al. analyzed the data of 178 patients with MM to evaluate whether antibiotic prophylaxis before dental procedures can prevent ONJ. The only variable significantly associated with ONJ was antibiotic prophylaxis, which had a protective effect [93].
Established ONJ should be managed conservatively; a BP “drug holiday” is usually indicated and invasive surgery should generally be avoided [94].

4.4 Bisphosphonates and Hematology: Not Only Multiple Myeloma

4.4.1 Bisphosphonates and Hematopoietic Cell Transplantation

Although BPs are frequently used in the treatment of MM patients, there are other hematologic conditions in which BPS might be used.
Long-term survivors of hematopoietic cell transplantation (HCT) are at risk for loss of bone mineral density (BMD) and subsequent osteoporosis. Bone loss occurs predominantly within the first 6–12 months after autologous and allogeneic HCT. Recovery first occurs in the lumbar spine and is followed by a slower recovery of BMD in the femoral neck. BMD may not return to baseline levels in patients with continuing exposure to corticosteroids and calcineurin inhibitors. There is a lack of clear guidelines for the screening, prevention, and treatment of bone loss after HCT. However, general interventions to reduce fracture risk, including adequate intake of calcium and vitamin D, are advised for all HCT recipients; where indicated, BPs can be used for the prevention or treatment of osteoporosis in adult HCT recipients [95].
Grade 2–4 acute graft versus host disease (GVHD) is associated with bone loss at 1 year after stem cell transplantation, whereas extensive chronic GVHD and steroid use are unfavorable prognostic factors in terms of osteopenia/osteoporosis at 2 years post-transplantation. The use of ZOL significantly prevented bone loss in the femoral neck and in the spine [96].

4.4.2 Bisphosphonate and Hypercalcemia

Hypercalcemia is a common metabolic complication of malignant disease and often requires emergency intervention. Although it is more frequently associated with solid tumors, malignancy-associated hypercalcemia (MAH) is seen in a significant number of patients with blood diseases, and its association with myeloma and adult T-cell leukemia/lymphoma is well recognized. BPs have revolutionized the management of MAH over the last 20 years [97]. They are also safely used in treating childhood hypercalcemia, secondary to acute lymphocytic leukemia [98, 99].

4.5 Anti-tumor Effects of Bisphosphonates in Multiple Myeloma

The option to use BPs in the treatment of MM recently received a new impulse by data showing that ZOL and PAM may have synergistic or additive effects with MM therapy and, in the future, might successfully be used in conjunction with other anti-myeloma agents. ZOL has been shown to decrease bone tumor burden in an established MM animal model [100102], while PAM has also shown anti-myeloma activity in animal models in vivo [103, 104].
Amino-bisphosphonates exert their anti-neoplastic effects by several mechanisms. It is well established that they inhibit the mevalonate pathway, thereby affecting cell function and survival duration. Nitrogen-containing bisphosphonates also have been shown to directly induce tumor apoptosis and inhibit angiogenesis, in addition to their actions on the immune system and osteoblasts [105107].
To study the inhibitory effect of ZOL on the growth and CD138 expression of myeloma cell line KM3, Hou et al. treated the cells with different concentrations of ZOL. The results showed that ZOL inhibited the growth of KM3 cells in a dose-dependent manner [108].
Moreover BPs induce significant expansion of γδ-T cells. In a study by Abe et al. ZOL-activated Vγ9γδT-lymphocyte-activated killer cells were administered to patients with MM. The results suggested that this strategy could be a safe and promising immunotherapy for the treatment of patients with MM [109].

4.6 Conclusions

The positive impact of BPs on the management of millions of patients with bone disorders has been enormous. These drugs have a pivotal role in the treatment of patients with malignant diseases involving bone, and thus a potentially enormous impact on the cost of disease treatment. In the USA, the national cost burden for patients with metastatic bone disease in 2004 dollars was estimated at $12.6 billion in total direct medical costs. In a recent study, 5.3% of cancer patients in the USA were projected to have metastatic bone disease. Hematologic disease was the leading cause, with MM accounting for 28.8% of these cases [110].
Currently, MM patients cannot be successfully managed without BPs. The recognition of ONJ as a late toxicity complication of BP treatment and the recent advances in basic and clinical research regarding the effects of BP therapy in the pathobiology of MM warrant an update in therapeutic strategies to redefine the balance between the risks and benefits of this class of drugs.
References
1.
Holmberg AR, Lerner UH, Alayia AA et al (2010) Development of a novel poly bisphosphonate conjugate for treatment of skeletal metastasis and osteoporosis. J Oncol 37(3):563–567
2.
Levy J, Roodman GD (2009) The role of bisphosphonates in multiple myeloma. Curr Hematol Malig Rep 4(2):108–112PubMedCrossRef
3.
Melton LJ 3rd, Kyle RA, Achenbach SJ et al (2005) Fracture risk with multiple myeloma: a population based study. J Bone Miner Res 20:487–493PubMedCrossRef
4.
Mahnken AH, Wildberger JE, Gehbauer G et al (2002) Multidetector CT of the spine in multiple myeloma: comparison with MR imaging and radiography. AJR 178:1429–1436PubMed
5.
Terpos E, Berenson J, Cook RJ et al (2010) Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease. Leukemia 24(5):1043–1049PubMedCrossRef
6.
Saad F, Lipton A, Cook R et al (2007) Pathological fractures correlate with reduced survival in patients with malignant bone disease. Cancer 110:1860–1867PubMedCrossRef
7.
Silvestris F, Cafforio P, Calvani N et al (2004) Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells. Br J Haematol 126(4):475–486PubMedCrossRef
8.
Tian E, Zhan F, Walker R et al (2003) The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349(26):2483–2494PubMedCrossRef
9.
Oshima T, Abe M, Asano J et al (2005) Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 106(9):3160–3165PubMedCrossRef
10.
Giuliani N, Colla S, Morandi F et al (2005) Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 106(7):2472–2483PubMedCrossRef
11.
Ehrlich LA, Chung HY, Ghobrial I et al (2005) IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood 106(4):1407–1414PubMedCrossRef
12.
Franchimont N, Rydziel S, Canalis E (2000) Transforming growth factor-beta increases interleukin-6 transcripts in osteoblasts. Bone 26(3):249–253PubMedCrossRef
13.
Hayashi T, Hideshima T, Nguyen AN et al (2004) Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. Clin Cancer Res 10(22):7540–7546PubMedCrossRef
14.
Silvestris F, Cafforio P, Tucci M et al (2003) Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone disease. Br J Haematol 122(1):39–52PubMedCrossRef
15.
Sati HIA, Greaves M, Apperley JF et al (1999) Expression of interleukin-1b and tumour necrosis factor-alpha in plasma cells from patients with multiple myeloma. Br J Haematol 104(2):350–357PubMedCrossRef
16.
Roux S, Mariette X (2004) The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-Kb) and RANK ligand expression. Leuk Lymphoma 45(6):1111–1118PubMedCrossRef
17.
Oyajobi BO, Mundy GR (2003) Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma. Cancer 97(3):813–817PubMedCrossRef
18.
Mitsiades CS, Mitsiades N, Hideshima T et al (2006) Proteasome inhibition as a new therapeutic principle in hematological malignancies. Curr Drug Targets 7(10):1341–1347PubMedCrossRef
19.
Tanaka Y, Abe M, Hiasa M et al (2007) Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin. Clin Cancer Res 13(3):816–823PubMedCrossRef
20.
Vogel CL, Yanagihara RH, Wood AJ et al (2004) Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy. Oncologist 9(6):687–695PubMedCrossRef
21.
Only gold members can continue reading. Log In or Register to continue

Nov 10, 2015 | Posted by in General Dentistry | Comments Off on Use of Bisphosphonates in Hematology
Premium Wordpress Themes by UFO Themes